Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme

Journal of Clinical Oncology

Volumn 26, Issue 34, 2008, Pages 5610-5617

  Reardon, David A ^a   Fink, Karen L ^b   Mikkelsen, Tom ^b   Cloughesy, Timothy F ^b   O'Neill, Alison ^b   Plotkin, Scott ^b   Glantz, Michael ^b   Ravin, Paula ^b   Raizer, Jeffrey J ^b   Rich, Keith M ^b   Schiff, David ^b   Shapiro, William R ^b   Burdette Radoux, Susan ^b   Dropcho, Edward J ^b   Wittemer, Sabine M ^b   Nippgen, Johannes ^b   Picard, Martin ^b   Nabors, L Burt ^b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CILENGITIDE; CORTICOSTEROID; GADOLINIUM; INTEGRIN; TEMOZOLOMIDE;

ADULT; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; BLOOD TOXICITY; BRAIN HEMORRHAGE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; FEBRILE NEUTROPENIA; FEMALE; GLIOBLASTOMA; HEADACHE; HUMAN; LEUKOPENIA; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PATIENT ASSESSMENT; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RECURRENT CANCER; SIDE EFFECT; THROMBOCYTOPENIA; WEIGHT GAIN;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; FEMALE; GLIOBLASTOMA; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; PEPTIDES, CYCLIC; QUALITY OF LIFE; SNAKE VENOMS; TREATMENT OUTCOME;

EID: 57149108506     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.16.7510     Document Type: Article

References (32)

1. Stupp R, Mason WP, van den Bent MJ, et al: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987-996, 2005
2. Reardon DA, Wen PY: Therapeutic advances in the treatment of glioblastoma: Rationale and potential role of targeted agents. Oncologist 11:152-164, 2006
3. Sathornsumetee S, Reardon DA, Desjardins A, et al: Molecularly targeted therapy for malignant glioma. Cancer 110:13-24, 2007
4. Tucker GC: Integrins: Molecular targets in cancer therapy. Curr Oncol Rep 8:96-103, 2006
5. Bello L, Francolini M, Marthyn P, et al: Alpha(v) beta3 and alpha(v) beta5 integrin expression in glioma periphery. Neurosurgery 49:380-389, 2001
6. Gingras MC, Roussel E, Bruner JM, et al: Comparison of cell adhesion molecule expression between glioblastoma multiforme and autologous normal brain tissue. J Neuroimmunol 57:143-153, 1995
7. Gladson CL: Expression of integrin alpha v beta 3 in small blood vessels of glioblastoma tumors. J Neuropathol Exp Neurol 55:1143-1149, 1996
8. Smith JW: Cilengitide Merck. Curr Opin Investig Drugs 4:741-745, 2003
9. Yamada S, Bu XY, Khankaldyyan V, et al: Effect of the angiogenesis inhibitor cilengitide (EMD 121974) on glioblastoma growth in nude mice. Neurosurgery 59:1304-1312, 2006
10. Taga T, Suzuki A, Gonzalez-Gomez I, et al: Alpha v-integrin antagonist EMD 121974 induces apoptosis in brain tumor cells growing on vitronectin and tenascin. Int J Cancer 98:690-697, 2002
11. Chatterjee S, Matsumura A, Schradermeier J, et al: Human malignant glioma therapy using antialpha(v) beta3 integrin agents. J Neurooncol 46:135-144, 2000
12. Lamfers ML, Grill J, Dirven CM, et al: Potential of the conditionally replicative adenovirus Ad5-Delta24RGD in the treatment of malignant gliomas and its enhanced effect with radiotherapy. Cancer Res 62:5736-5742, 2002
13. MacDonald TJ, Taga T, Shimada H, et al: Preferential susceptibility of brain tumors to the antiangiogenic effects of an alpha(v) integrin antagonist. Neurosurgery 48:151-157, 2001
14. Tonn JC, Wunderlich S, Kerkau S, et al: Invasive behaviour of human gliomas is mediated by interindividually different integrin patterns. Anticancer Res 18:2599-2605, 1998
15. Germer M, Kanse SM, Kirkegaard T, et al: Kinetic analysis of integrin-dependent cell adhesion on vitronectin: The inhibitory potential of plasminogen activator inhibitor-1 and RGD peptides. Eur J Biochem 253:669-674, 1998
16. Eskens FA, Dumez H, Hoekstra R, et al: Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of cilengitide (EMD 121974), a novel inhibitor of the integrins alphavbeta3 and alphavbeta5 in patients with advanced solid tumours. Eur J Cancer 39:917-926, 2003
17. Nabors LB, Mikkelsen T, Rosenfeld SS, et al: Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma. J Clin Oncol 25:1651-1657, 2007
18. Macdonald DR, Cascino TL, Schold SC Jr, et al: Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8:1277-1280, 1990
19. Yung WK, Albright RE, Olson J, et al: A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 83:588-593, 2000
20. Akella NS, Twieg DB, Mikkelsen T, et al: Assessment of brain tumor angiogenesis inhibitors using perfusion magnetic resonance imaging: Quality and analysis results of a phase I trial. J Magn Reson Imaging 20:913-922, 2004
21. Chang SM, Kuhn J, Wen P, et al: Phase I/pharmacokinetic study of CCI-779 in patients with recurrent malignant glioma on enzyme-inducing antiepileptic drugs. Invest New Drugs 22:427-435, 2004
22. Cloughesy TF, Wen PY, Robins HI, et al: Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: A North American Brain Tumor Consortium Study. J Clin Oncol 24:3651-3656, 2006
23. Galanis E, Buckner JC, Maurer MJ, et al: Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: A North Central Cancer Treatment Group study. J Clin Oncol 23:5294-5304, 2005
24. Rich JN, Reardon DA, Peery T, et al: Phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol 22:133-142, 2004
25. Wen PY, Yung WK, Lamborn KR, et al: Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08. Clin Cancer Res 12:4899-4907, 2006
26. Gilbert M, Lamborn K, Lassman AB, et al: Tumor tissue delivery of cilengitide after intravenous administration to patients with recurrent glioblastoma (GBM): Preliminary data from NABTC protocol 03-02. 12th Annual Meeting of the Society for Neuro-Oncology, Dallas, TX, November 15-18, 2007 (abstr 525)
27. Abdollahi A, Griggs DW, Zieher H, et al: Inhibition of alpha(v) beta3 integrin survival signaling enhances antiangiogenic and antitumor effects of radiotherapy. Clin Cancer Res 11:6270-6279, 2005
28. Albert JM, Cao C, Geng L, et al: Integrin alpha v beta 3 antagonist cilengitide enhances efficacy of radiotherapy in endothelial cell and non-small-cell lung cancer models. Int J Radiat Oncol Biol Phys 65:1536-1543, 2006
29. Burke PA, DeNardo SJ, Miers LA, et al: Cilengitide targeting of alpha(v) beta(3) integrin receptor synergizes with radioimmunotherapy to increase efficacy and apoptosis in breast cancer xenografts. Cancer Res 62:4263-4272, 2002
30. Friess H, Langrehr JM, Oettle H, et al: A randomized multi-center phase II trial of the angiogenesis inhibitor cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unresectable pancreatic cancer. BMC Cancer 6:285, 2006
31. Raguse JD, Gath HJ, Bier J, et al: Cilengitide (EMD 121974) arrests the growth of a heavily pretreated highly vascularised head and neck tumour. Oral Oncol 40:228-230, 2004
32. Stupp R, Goldbrunnr R, Neyns B, et al: Phase I/IIa trial of cilengitide (EMD121974) and temozolomide with concomitant radiotherapy, followed by temozolomide and cilengitide maintenance therapy in patients (pts) with newly diagnosed glioblastoma (GBM). J Clin Oncol 25:75s, 2007 (suppl; abstr 2000)